文献速递银屑病与炎症性皮肤病

银屑病二线生物制剂药物存留差异:BADBIR队列研究

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
PubMed 文献 · J Invest Dermatol · 2017-12-06

基于英国BADBIR多中心药物警戒登记,纳入1,239例一线生物制剂失败后换用二线治疗(阿达木单抗538例、依那西普104例、乌司奴单抗597例)的银屑病患者,评估二线药物存留。换药后第1年总体存留率77%(95%CI 74-79%),第3年降至58%(55-61%);依那西普较阿达木单抗更易停药,乌司奴单抗更易持续。

要点

  • 二线生物制剂总体药物存留率第1年77%,第3年降至58%
  • 与阿达木单抗相比,依那西普停药风险更高(HR=1.87),乌司奴单抗更易持续(HR=0.46)
  • 一线因不良事件停药者,二线因不良事件停药风险升高(HR=2.55)

核心结论

  • 二线生物制剂药物存留率因药物而异并随时间下降。
  • 一线因不良事件停药者,二线因不良事件停药更常见。
  • 结果可支持银屑病二线生物制剂的临床决策。

研究设计与样本

  • 多中心药物警戒登记(BADBIR)观察性队列研究。
  • 纳入一线生物制剂失败后换用二线的银屑病患者n=1,239。
  • 二线药物:阿达木单抗n=538、依那西普n=104、乌司奴单抗n=597。

主要发现

  • 换药后第1年总体药物存留率77%(95%CI 74-79%),第3年58%(55-61%)。
  • 女性、多种合并症、合用环孢素及换药时PASI高是全因停药的预测因素(多变量Cox比例风险模型)。
  • 与阿达木单抗相比,依那西普停药风险更高(HR=1.87,95%CI 1.24-2.83),乌司奴单抗更易持续(HR=0.46,95%CI 0.33-0.64)。
  • 一线因不良事件停药与二线因不良事件停药风险升高相关(HR=2.55,95%CI 1.50-4.32)。

关键数值与推荐

  • 二线换药后第1年药物存留率77%(95%CI 74-79%),第3年58%(55-61%)。
  • 依那西普vs阿达木单抗停药HR=1.87(95%CI 1.24-2.83)。
  • 乌司奴单抗vs阿达木单抗停药HR=0.46(95%CI 0.33-0.64)。
  • 一线因不良事件停药与二线因不良事件停药HR=2.55(95%CI 1.50-4.32)。

临床怎么用

  • 选择二线生物制剂时可参考不同药物的药物存留差异。
  • 对女性、多种合并症、合用环孢素及换药时PASI高者应关注停药风险。
  • 一线因不良事件停药者换用二线时需警惕再次因不良事件停药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Little is known about the drug survival of second-line biologic therapies for psoriasis in routine clinical practice. We assessed drug survival of second-line biologic therapies and estimated the risk of recurrent discontinuation due to adverse events or ineffectiveness in patients with psoriasis who had failed a first biologic therapy and switched to a second in a large, multicenter pharmacovigilance registry (n = 1,239; adalimumab, n = 538; etanercept, n = 104; ustekinumab, n = 597). The overall drug survival rate in the first year after switching was 77% (95% confidence interval = 74-79%), falling to 58% (55-61%) in the third year. Female sex, multiple comorbidities, concomitant therapy with cyclosporine, and a high Psoriasis Area and Severity Index at switching to the second-line biologic therapy were predictors of overall discontinuation (multivariable Cox proportional hazard model). Compared to adalimumab, patients receiving etanercept were more likely to discontinue therapy (hazard ratio = 1.87, 95% confidence interval = 1.24-2.83), whereas patients receiving ustekinumab were more likely to persist (hazard ratio = 0.46; 95% confidence interval = 0.33-0.64). Discontinuation of the first biologic therapy because of adverse events was associated with an increased rate of second drug discontinuation because of adverse events (hazard ratio = 2.55; 95% confidence interval = 1.50-4.32). In conclusion, drug survival rates differed among biologic therapies and decreased over time; second-line discontinuation because of adverse events was more common among those who discontinued first-line treatment for this reason. The results of this study should support clinical decision making when choosing second-line biologic therapy for patients with psoriasis.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Iskandar IYK, Warren RB, Lunt M, et al. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2017. PMID: 29080680. doi:10.1016/j.jid.2017.09.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。